Infliximab in severe active ankylosing spondylitis with spinal ankylosis.

BACKGROUND: Infliximab is an anti-tumour necrosis factor monoclonal antibody, which significantly improves pain, stiffness and functional disability outcomes in patients with active ankylosing spondylitis. There are limited data available on the efficacy of this treatment for the subgroup with established spinal ankylosis. AIM: To compare the treatment response of infliximab in active severe ankylosing spondylitis for patients with and without radiographic evidence of spinal ankylosis in the clinical practice setting. METHODS: Twenty-seven patients with mean Bath Ankylosing Spondylitis Disease Activity Index of 8.7, all HLA-B27 positive, with 11 (41%) having spinal ankylosis, were studied for 54 weeks. The qualification for initial and ongoing infliximab treatment was defined by the Australian Pharmaceutical Benefit Schedule (PBS), and 5 mg/kg of infliximab was given at 0 week (baseline), repeated at 2 and 6 weeks and every 6 weeks thereafter. At each time point, PBS-mandated and international consensus response measures were completed. Disease activity and outcome measures for spinal ankylosis subgroup and those who did not have spinal ankylosis were cross-sectionally compared at baseline and 1 year. RESULTS: Patients with spinal ankylosis tended to be older (P = 0.01). Although the subgroup with spinal ankylosis had higher baseline activity scores, the only significant difference between the subgroups was the degree of morning stiffness (P = 0.04). By 54 weeks, all patients including the subgroup with spinal ankylosis fulfilled the PBS criteria for continuation of treatment. Majority of patients including the subgroup with spinal ankylosis achieved the various international consensus response measures. Patients with spinal ankylosis also experienced significant improvements in health-related quality of life, with majority returning to full-time employment by 1 year. CONCLUSION: In real-life clinical practice, patients with established disease with spinal ankylosis and high levels of inflammation and disease activity can achieve a major clinical response with infliximab.

Etanercept in severe active rheumatoid arthritis: first Australian experience.

BACKGROUND: Etanercept reduces disease activity in adults with chronic rheumatoid arthritis (RA) who are resistant to other therapies. Medicare Australia Pharmaceutical Benefit Scheme subsidized treatment (since August 2003) restricts etanercept availability to a most drug-resistant RA population. The aim of the study was to assess the efficacy of etanercept in this unique group after 12 months of therapy. METHODS: A prospective study of the first 50 consecutive private practice, adult RA patients whom were commenced on etanercept. The primary efficacy measures included short form 36 scores, Disease Activity Score 28, American College of Rheumatology (ACR) response improvement in per cent and the ACR individual core set components at baseline, 3 and 12 months. Analysis was by intention to treat. RESULTS: There was significant improvement in all mean short form 36 component scores (P < 0.05) and all ACR core set component scores (P < 0.05) comparing 12 months to baseline. The disease activity score 28 also significantly fell from baseline at both 3 and 12 months (P < 0.05). The ACR 20% response significantly improved (P < 0.05) both at baseline to 3 months 92% (81.2, 96.9) and to 12 months 80% (67.0, 88.8). Serious adverse events occurred in 16%. At 12 months 88% completed treatment. CONCLUSION: Etanercept therapy will, by 3 and 12 months, significantly improve the short form 36, disease activity score 28, ACR 20% response and core set components. Our results are similar to international studies using etanercept in efficacy and tolerance despite our cohort being more resistant to preceding drug therapy. Etanercept offers this unique active severe refractory late RA Australian population a new therapeutic option to control their disease.

The experience of nausea during sustained hyper-gravity flight with negligible angular velocity.

BACKGROUND: The purpose of this study was to investigate nausea and vomiting during hyper-gravity flight at a slow rate of turn. During head-movements under these conditions, the semi-circular canals of the vestibular system function normally whereas the otoliths experience a G-excess effect, displacing further and moving faster than in a 1 G field. HYPOTHESIS: Nausea and vomiting are greater during hyper-gravity flight compared with historical data collected in a 1 G field at a similar rate of turn. METHODS: There were 27 subjects who were exposed to 1.8 G (hyper-G) during a slow rate turn on three NASA KC-135 flights. Subjects participated in one of three experimental periods, each period consisting of two 5.5-min hyper-G runs: 1) rest, with only incidental head movements; 2) active roll and pitch head movements; or 3) passive roll head movements. Subjective symptom data were collected pre-flight, following each experimental period and post-flight using a standardized nausea questionnaire. Electrogastrograms were obtained from eight subjects. RESULTS: Seven subjects (26%) vomited during the flight. Nausea initially increased but was then stable throughout the flight. Nausea appeared highest during active head movements. In subjects who vomited, greater gastrointestinal distress and somatic distress were reported. CONCLUSIONS: The levels of nausea and vomiting observed during hyper-G cannot be explained by Coriolis cross coupling and are likely due to the G-excess effect on the otoliths. The nausea profiles observed in individuals who vomit during hyper-G appear similar to those previously observed during nausea produced by an optokinetic drum stimulus in a 1-G field.

Clinical features and associated radiological abnormalities in 54 patients with cavum septi pellucidi.

PURPOSE: To determine the clinical and radiological features of the patients who were found to have cavum septum pellucidum (CSP) on the cranial computerized tomographic (CT) scans. METHODS: Fifty four consecutive cases of cavum septum pellucidum were detected amongst 1,281 patients who underwent cranial CT scans; their clinical and radiological features were studied. RESULTS: Recurrent seizures and developmental delay were the commonest presenting symptoms seen. Significant neurological deficits were present in 75.9% of these cases. Additional cerebral abnormalities were observed in the CT scan in 76% of cases, the commonest being cortical atrophy, cerebral infarction and hydrocephalus. CONCLUSIONS: There seems to be a strong association between CSP and certain neurological abnormalities in the population studied. Further interpretation of this study would be possible if normal population in this geographical area is screened for CSP using cranial CT scans or magnetic resonance imaging.

Cytogenetic analysis of children suspected of chromosomal abnormalities.

Karyotypes were examined in 122 Omani children suspected of having chromosomal abnormalities. A total of 50 (41 per cent) had an abnormal karyotype: 38 (31 per cent) were Down's syndrome whilst a further 12 (10 per cent) had other types of chromosomal abnormalities. These findings suggest that cytogenetic analysis is useful in the investigations of children with congenital anomalies of unknown origin; to confirm clinical diagnosis in children with known cytogenetic syndromes and for genetic counselling.